{"title":"Fremanezumab延迟注射部位反应治疗慢性偏头痛。","authors":"Kevin V Thomas, Daniel D Bennett, Justin Endo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fremanezumab is a humanized monoclonal antibody administered through a subcutaneous injection. It is used for treatment of migraines, and occasional injection site reactions have developed after usage.</p><p><strong>Case presentation: </strong>This case report describes a nonimmediate injection site reaction on the right thigh of a 25-year-old female patient after starting treatment with fremanezumab. The injection site reaction presented as 2 warm, red annular plaques 8 days following a second injection of fremanezumab and about 5 weeks following the first injection. She was prescribed a 1-month course of prednisone that relieved her symptoms of redness, itching, and pain.</p><p><strong>Discussion: </strong>Similar nonimmediate injection site reactions have been reported before, but this particular injection site reaction was significantly more delayed.</p><p><strong>Conclusions: </strong>Our case illustrates that injection site reactions to fremanezumab can be delayed after the second dose and may require systemic therapy to alleviate symptoms.</p>","PeriodicalId":38747,"journal":{"name":"Wisconsin Medical Journal","volume":"122 2","pages":"146-148"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delayed Injection Site Reaction to Fremanezumab for Chronic Migraine Treatment.\",\"authors\":\"Kevin V Thomas, Daniel D Bennett, Justin Endo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Fremanezumab is a humanized monoclonal antibody administered through a subcutaneous injection. It is used for treatment of migraines, and occasional injection site reactions have developed after usage.</p><p><strong>Case presentation: </strong>This case report describes a nonimmediate injection site reaction on the right thigh of a 25-year-old female patient after starting treatment with fremanezumab. The injection site reaction presented as 2 warm, red annular plaques 8 days following a second injection of fremanezumab and about 5 weeks following the first injection. She was prescribed a 1-month course of prednisone that relieved her symptoms of redness, itching, and pain.</p><p><strong>Discussion: </strong>Similar nonimmediate injection site reactions have been reported before, but this particular injection site reaction was significantly more delayed.</p><p><strong>Conclusions: </strong>Our case illustrates that injection site reactions to fremanezumab can be delayed after the second dose and may require systemic therapy to alleviate symptoms.</p>\",\"PeriodicalId\":38747,\"journal\":{\"name\":\"Wisconsin Medical Journal\",\"volume\":\"122 2\",\"pages\":\"146-148\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Wisconsin Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wisconsin Medical Journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Delayed Injection Site Reaction to Fremanezumab for Chronic Migraine Treatment.
Introduction: Fremanezumab is a humanized monoclonal antibody administered through a subcutaneous injection. It is used for treatment of migraines, and occasional injection site reactions have developed after usage.
Case presentation: This case report describes a nonimmediate injection site reaction on the right thigh of a 25-year-old female patient after starting treatment with fremanezumab. The injection site reaction presented as 2 warm, red annular plaques 8 days following a second injection of fremanezumab and about 5 weeks following the first injection. She was prescribed a 1-month course of prednisone that relieved her symptoms of redness, itching, and pain.
Discussion: Similar nonimmediate injection site reactions have been reported before, but this particular injection site reaction was significantly more delayed.
Conclusions: Our case illustrates that injection site reactions to fremanezumab can be delayed after the second dose and may require systemic therapy to alleviate symptoms.
期刊介绍：
The Wisconsin Medical Society is the largest association of medical doctors in the state with more than 12,000 members dedicated to the best interests of their patients. With that in mind, wisconsinmedicalsociety.org offers patients a unique source for reliable, physician-reviewed medical information. The Wisconsin Medical Society has been a trusted source for health policy leadership since 1841.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
